上尿路尿路上皮癌患者术后尿路外复发影响因素及危险度分层分析

doi:10.19558/j.cnki.10-1020/r.2021.03.006

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1003 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要 目的：探讨上尿路尿路上皮癌（UTUC）患者术后尿路外复发影响因素及危险分层价值。方法：回顾性分析2010年1月–2014年12月收治135例行根治手术治疗UTUC患者临床资料,采用单因素和多因素法分析术后尿路外复发影响因素,同时根据危险度分层比较随访无局部复发生存率和无远处转移生存率。结果：①无蒂状肿瘤、多病灶、输尿管癌、淋巴脉管侵犯、病理分期≥T₃期、eGFR<60 mL·min^-1·1.73 m^-2）及Fib≥3.2 g/L患者无局部复发生存率均显著低于其他患者（P<0.05）;肿瘤分级G₃级、无蒂状肿瘤、淋巴脉管侵犯、中重度肾盂积水及中性粒-淋巴细胞比值>2.0患者无远处转移生存率均显著低于其他患者（P<0.05）;②多因素分析结果提示,输尿管癌、淋巴脉管侵犯、病理分期≥T₃期及Fib≥3.2 g/L均是患者无局部复发生存率独立危险因素（P<0.05）;无蒂状肿瘤、淋巴脉管侵犯及中性粒-淋巴细胞比值>2.0均是患者无远处转移生存率独立危险因素（P<0.05）;③低危组随访1、3、5年无局部复发生存率显著高于中危组和高危组（P<0.05）;低危组随访1、3、5年无远处转移生存率显著高于中危组和高危组（P<0.05）。结论：输尿管癌、淋巴脉管侵犯、病理分期≥T₃期及Fib≥3.2 g/L与UTUC患者术后局部复发密切相关;而无蒂状肿瘤、淋巴脉管侵犯及中性粒-淋巴细胞比值>2.0则可增加术后远处转移风险;根据相关独立危险因素进行危险度分层能够有效预测患者临床预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	郭雪涛
	邵鸿江
	张强
	王昕
	张飞
	霍日查
	张晓春
	毛全宗

关键词 ：上尿路尿路上皮癌, 手术, 尿路外复发, 影响因素, 危险度

Abstract：Objective： To investigate the influencing factors of postoperative extra-urinary tract recurrence and risk stratification in patients with upper tract urothelial carcinoma （UTUC）. Methods： Clinical data of 135 patients with UTUC were retrospectively chosen in the period from January 2010 to December 2014. Univariate and multifactorial methods were used to analyze the influencing factors of postoperative extra-urinary tract recurrence, and the local recurrence-free survival （IRFS） rate and distant metastasis-free survival （dMFS） rate were compared according to risk stratification. Results： ① The IRFS rate in patients with non-pedicle tumor, multiple lesions, ureteral cancer, lymphatic vascular invasion, pathological stage ≥ T₃, eGFR < 60 mL•min^-1•1.73 m^-2） and Fib ≥ 3.2 g/L was significantly lower than other patients （P < 0.05）. The dMFS in patients with tumor grade for G₃, non-pedicle tumor, lymphatic vascular invasion, moderate and severe hydronephrosis, and neutro-lymphocyte ratio > 2.0 was significantly lower than other patients （P < 0.05）. ② The multivariate analysis indicated that ureteral cancer, lymphatic vascular invasion, pathological stage ≥ T₃ and Fib ≥ 3.2 g/L were all independent risk factors for IRFS rate （P < 0.05）. The non-pedicle tumor, lymphatic vascular invasion and neutro-lymphocyte ratio > 2.0 were all independent risk factors for dMFS rate （P < 0.05）. ③ The 1-, 3- and 5-year IRFS rate during the follow-up period in the low-risk group was significantly higher than that in medium-risk group and high-risk group （P < 0.05）. The 1-, 3- and 5-year dMFS rate during the follow-up period in low-risk group was significantly higher than that in medium-risk group and high-risk group （P < 0.05）. Conclusion： Ureteral cancer, lymphatic vascular invasion, pathological stage ≥ T₃ and Fib ≥ 3.2 g/L were closely related to postoperative local recurrence of patients with UTUC and the non-pedicle tumor, lymphatic vascular invasion and neutro-lymphocyte ratio > 2.0 increased the risk of postoperative distant metastasis. Risk stratification based on relevant independent risk factors can effectively predict the clinical prognosis of patients.

Key words： upper urinary tract urothelial carcinoma surgery extra-urinary recurrence influencing factors risk degree

收稿日期: 2020-01-02

通讯作者: 郭雪涛,guoxt681205@163.com

引用本文:

郭雪涛, 邵鸿江, 张强, 王昕, 张飞, 霍日查, 张晓春, 毛全宗. 上尿路尿路上皮癌患者术后尿路外复发影响因素及危险度分层分析[J]. 微创泌尿外科杂志, 2021, 10(3): 174-179.
GUO Xuetao, SHAO Hongjiang, ZHANG Qiang, WANG Xin, ZHANG Fei, HUO Richa, ZHANG Xiaochun, MAO Quanzong. Influencing factors of postoperative extra-urinary tract recurrence and risk stratification analysis in patients with UTUC. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2021, 10(3): 174-179.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1677.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2021/V10/I3/174

[1] 郑铎,刘隽垚,齐鹏,等.上尿路尿路上皮癌术后膀胱内复发危险因素的研究进展.中华泌尿外科杂志,2017,38(5):395-397.
[2] 韩雪冰,刘建武,庞东梓,等.125I放射性粒子植入联合手术和化疗治疗局部晚期上尿路尿路上皮癌的疗效分析.中华泌尿外科杂志,2017,38(12):905-909.
[3] GREGG RW, VERA-BADILLO FE, BOOTH CM, et al.Perioperative chemotherapy for urothelial carcinoma of the upper urinary tract: A systematic review and meta-analysis. Crit Rev Oncol Hematol, 2018,128(8):58-64.
[4] MBEUTCHA A, ROUPRÊT M, KAMAT AM, et al. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol, 2017,35(3):337-353.
[5] 中国医师协会泌尿外科医师分会肿瘤专业委员会,中国医师协会泌尿外科,医师分会上尿路尿路上皮癌(CUDA-UTUC)协作组.上尿路尿路上皮癌诊断与治疗中国专家共识.中华泌尿外科杂志,2018,39(7):485-488.
[6] 冯炳富,罗勇,魏德超,等.根治术联合辅助化疗对高风险上尿路尿路上皮癌患者生存预后的影响.中华医学杂志,2019,99(2):115-119.
[7] 袁易初,黄吉炜,陈勇辉,等.淋巴血管侵犯对行上尿路尿路上皮癌根治术患者预后的影响.中华泌尿外科杂志,2017,38(12):891-895.
[8] KISHIMOTO N, TAKAO T, KURIBAYASHI S, et al.The neutrophil-to-lymphocyte ratio as a predictor of intravesical recurrence in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy. Int J Clin Oncol, 2017,22(1):153-158.
[9] KOBAYASHI H, KIKUCHI E, TANAKA N, et al.Patient age was an independent predictor of cancer-specific survival in male patients with upper tract urothelial carcinoma treated by radical nephroureterectomy. Jpn J Clin Oncol, 2016,46(6):554-559.
[10] LEE CH, KU JY, JEONG CW, et al.Predictors for intravesical recurrence following radical nephroureterectomy for upper tract urothelial carcinoma: a national multicenter analysis. Clin Genitourin Cancer, 2017,15(6):e1055-e1061.
[11] MOMOTA M, HATAKEYAMA S, YAMAMOTO H, et al.Risk-stratified surveillance protocol improves cost-effectiveness after radical nephroureterectomy in patients with upper tract urothelial carcinoma. Oncotarget, 2018,9(33):23047-23057.
[12] SORIA F, SHARIAT SF, LERNER SP, et al.Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol, 2017,35(3):379-387.
[13] KIM HS, JEONG CW, KWAK C, et al.Association between demographic factors and prognosis in urothelial carcinoma of the upper urinary tract: a systematic review and meta-analysis. Oncotarget, 2017,8(5):7464-7476.
[14] HARPER HL, MCKENNEY JK, HEALD B, et al.Upper tract urothelial carcinomas: frequency of association with mismatch repair protein loss and lynch syndrome. Mod Pathol, 2017,30(1):146-156.
[15] QIN C, LIANG EL, DU ZY, et al.Prognostic significance of urothelial carcinoma with divergent differentiation in upper urinary tract after radical nephroureterectomy without metastatic diseases: A retrospective cohort study. Medicine (Baltimore), 2017,96(21):e6945.
[16] CHEN CH, DICKMAN KG, HUANG CY, et al.Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma. Oncotarget, 2016,7(29):45225-45236.